Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products.
about
Discovery and resupply of pharmacologically active plant-derived natural products: A reviewA comparison of the anatomical structure of the pancreas in experimental animalsMicturition in Göttingen minipigs: first reference in vivo data for urological research and review of literature.The minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.Monosodium L-glutamate and dietary fat exert opposite effects on the proximal and distal intestinal health in growing pigs.Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.Monosodium L-Glutamate and Dietary Fat Differently Modify the Composition of the Intestinal Microbiota in Growing Pigs.Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature SwineMolecular cloning, characterization and expression of the energy homeostasis-associated gene in pigletA single oral dose of a polyglucosamine influences the bioavailability of [9-(14)C]-Oleic acid in adult female Göttingen minipigsMinipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.The using of a piglets as a model for evaluating the dipyrone hematological effects.Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.Performance of conventional pigs and Göttingen miniature pigs in a spatial holeboard task: effects of the putative muscarinic cognition impairer Biperiden.Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.Biological Characteristics of Captive Chinese Wuzhishan Minipigs (Sus scrofa).Both dietary supplementation with monosodium L-glutamate and fat modify circulating and tissue amino acid pools in growing pigs, but with little interactive effect.Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute.The pig as an experimental model for clinical craniofacial research.Animal models of toxicology testing: the role of pigs.Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: where are we now? Where are we going?The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.The Yucatan Minipig Temporomandibular Joint Disc Structure-Function Relationships Support Its Suitability for Human Comparative Studies.Development of a guinea pig cutaneous radiation injury model using low penetrating X-rays.A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry.Characterization of the T-dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) in the Göttingen minipig.Cutaneous Candidiasis in a Gottingen Minipig: A Potential Pitfall in Preclinical Studies.The minipig as nonrodent species in toxicology--where are we now?The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.Onset of puberty and normal histological appearances of the reproductive organs in peripubertal female Göttingen minipigs.Trauma as a Cause for Hepatopathy in Newborn Göttingen Minipigs
P2860
Q22252341-056FB57F-5ABF-45FA-A0DF-34BC4723E513Q26738995-EE6A6BE4-4F95-4544-BD54-13A5FB135B97Q30889293-337D970A-1ADB-4686-8E3D-4AEB3FF101C7Q33427938-155A522D-AAF5-4873-9475-8DB899C0541EQ35579440-589EC6C4-F62E-474C-9CAD-60A86901B14CQ35580799-F8247657-57E4-42A3-BEC0-610173CA6AAEQ35581761-C0A98673-2CE3-4185-A0B0-3F79FECD50A9Q35610499-55360F88-BCC4-4A19-AB41-F6678807FE98Q35753781-B273397B-60AD-4ED2-84B4-74E28660BDD9Q35962039-C25F8755-6D30-4CDD-9B14-BA893376AD57Q35992509-C08687DB-D9DD-402E-BC0C-400C0FCB3270Q36203571-00DDC3FF-A000-4038-9A96-8A6109D7B01CQ36331497-54AB3AFF-5B70-4A1D-8AEF-61FE152F72CEQ36585301-96CBBD88-9EF3-41AF-AE67-647C508F413FQ36951897-918EC1AA-EBD8-40AD-812A-369FDC267E06Q36979397-1C2721BF-86BE-4E0B-9430-F3FBC42D8F81Q37499174-685108DE-7B2E-4299-92DD-51356DFF2FE0Q37902619-B4F31D57-BCEC-479D-AD1C-D214C5FB1E27Q37970729-5A868484-2AB9-416E-910D-0CC4103F495CQ38042588-E1537335-7C5F-47B1-85D9-876255A706C0Q38065254-5C5FAB62-EA76-44E6-A208-B54FB65863DAQ39548977-6DA5AAC8-737B-4FB4-8460-B3AFC17AD727Q39742342-B9341E17-9B55-4533-A94E-C93928094103Q39896328-08C5B72F-A6F1-4BA6-B5C0-C9CA4BF3E034Q40473656-ADF3C634-DA47-48F1-8C34-D239C68D607CQ46397378-E7062AC8-873C-4669-ADE2-6F0116A9151AQ46405904-573BA851-F9AB-43DE-A672-5AE91FA7C527Q46972712-A1B8686E-CBF8-41C4-949C-D3E0E9FC7326Q49997117-FA559647-73BA-4EC5-98F4-C66CAD738E52Q50776657-636F84DE-6565-4983-8B04-D13F114C8C66Q50935053-27DA654B-8CE1-437B-BC64-DF73035AFF01Q51245437-BEECE9F8-890F-433A-B3D8-EBC8FD7A4693Q58802757-0DDBF31A-4832-4986-8192-1661767BFA30
P2860
Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulatory acceptability of th ...... chemicals and other products.
@en
Regulatory acceptability of th ...... chemicals and other products.
@nl
type
label
Regulatory acceptability of th ...... chemicals and other products.
@en
Regulatory acceptability of th ...... chemicals and other products.
@nl
prefLabel
Regulatory acceptability of th ...... chemicals and other products.
@en
Regulatory acceptability of th ...... chemicals and other products.
@nl
P2093
P1476
Regulatory acceptability of th ...... chemicals and other products.
@en
P2093
Claudia Stark
Jan Willem van der Laan
John Brightwell
Joszef Ratky
Peter McAnulty
Steering Group of the RETHINK Project
P304
P356
10.1016/J.VASCN.2010.05.005
P577
2010-06-16T00:00:00Z